Amneal Pharmaceuticals, Inc. (AMRX)

NASDAQ: AMRX · Real-Time Price · USD
7.46
+0.24 (3.32%)
May 8, 2025, 4:00 PM EDT - Market closed
3.32%
Market Cap 2.34B
Revenue (ttm) 2.83B
Net Income (ttm) -13.05M
Shares Out 313.42M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE 11.17
Dividend n/a
Ex-Dividend Date n/a
Volume 1,681,416
Open 7.28
Previous Close 7.22
Day's Range 7.27 - 7.58
52-Week Range 5.18 - 9.48
Beta 1.17
Analysts Strong Buy
Price Target 10.80 (+44.77%)
Earnings Date May 2, 2025

About AMRX

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm... [Read more]

Sector Healthcare
Founded 2002
Employees 8,300
Stock Exchange NASDAQ
Ticker Symbol AMRX
Full Company Profile

Financial Performance

In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price forecast is $10.8, which is an increase of 44.77% from the latest price.

Price Target
$10.8
(44.77% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.

-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal's extensive domestic pharmaceu...

18 hours ago - GlobeNewsWire

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q1 2025 Earnings Call May 2, 2025 8:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Off...

6 days ago - Seeking Alpha

Amneal Reports First Quarter 2025 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS.

6 days ago - Business Wire

Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month.

27 days ago - Business Wire

Amneal to Report First Quarter 2025 Results on May 2, 2025

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report First Quarter 2025 Results on May 2, 2025.

4 weeks ago - Business Wire

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease

BRIDGEWATER, N.J.--(BUSINESS WIRE)--New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® Extended-Release Capsules in Parkinson's Disease.

4 weeks ago - Business Wire

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.

5 weeks ago - Business Wire

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, and Shilpa Medicare Limited (“Shilpa”) today announced ...

5 weeks ago - Business Wire

Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued

Amneal Pharmaceuticals, Inc. seems fundamentally undervalued, with a market cap significantly lower than peers despite similar revenue levels, suggesting potential for substantial stock price apprecia...

7 weeks ago - Seeking Alpha

Amneal to Participate at Upcoming Investor Conference

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conference.

2 months ago - Business Wire

Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA.

2 months ago - Business Wire

Amneal Pharmaceuticals, Inc. (AMRX) Q4 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-C...

2 months ago - Seeking Alpha

Amneal Reports Fourth Quarter and Full Year 2024 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Fourth Quarter and Full Year 2024 Financial Results.

2 months ago - Business Wire

Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

J.P. Morgan has upgraded Amneal Pharmaceuticals, Inc AMRX, noting the company's generics business is increasingly well-positioned with a solid Crexont launch and continued momentum across the portfoli...

2 months ago - Benzinga

Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide.

2 months ago - Business Wire

Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025.

3 months ago - Business Wire

Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine/done...

3 months ago - Business Wire

Amneal to Participate at Upcoming Investor Conferences

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Participate at Upcoming Investor Conferences.

5 months ago - Business Wire

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.

6 months ago - Business Wire

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chie...

6 months ago - Seeking Alpha

Amneal Reports Third Quarter 2024 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results.

6 months ago - Business Wire

Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets.

7 months ago - Business Wire

Amneal to Report Third Quarter 2024 Results on November 8, 2024

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal to Report Third Quarter 2024 Results on November 8, 2024.

7 months ago - Business Wire

Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases

BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and Metsera, Inc. (“Metsera”), a clinical-stage...

7 months ago - Business Wire

Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson's Disease.

8 months ago - Business Wire